Characteristic Study ID	Intervention(s) and control(s)	Country	Duration of intervention	Duration of follow‐up	Co‐medications	Co‐morbidities
Auvichayapat 2008	I1: green tea extract C1: placebo	Thailand	12 weeks	‐	Participants were excluded if taking prescribed medications, (e.g. antipsychotics, antidepressants, anti‐obesity medications, hormonal therapy)	Participants were excluded if they had a history of metabolic disease (e.g. diabetes mellitus, hyper‐ or hypothyroidism, Cushing's syndrome) or systemic disease, (e.g. heart, renal, liver disease)
Diepvens 2005	I1: green tea C1: placebo	The Netherlands	84 days	‐	Excluded if on medications	Excluded if not healthy
Hill 2007	I1: green tea extract C1: placebo	Australia	12 weeks	‐	Antihypertensive, lipid‐lowering or obesity medications not allowed	Note: participants excluded if had diabetes, liver, gastrointestinal or CV disease, or abnormal thyroid function
Hsu 2008	I1: green tea extract C1: placebo	Taiwan	12 weeks	‐	Obesity medications not allowed – no other details provided	‐
Hursel 2009	I1: green tea‐caffeine mixture + AP diet I2: green tea‐caffeine mixture + HP diet C1: placebo + AP diet C2: placebo + HP diet	The Netherlands	3 months	‐	Medication use not permitted	Participants had to be in good health, no further details were provided
Kajimoto 2005	I1: catechin drink – low dose group I2: catechin drink – high dose group C1: placebo drink	Japan	12 weeks	8‐week withdrawal period	Participants were excluded if taking medicines that might affect lipid metabolism	‐
Kataoka 2004	I1: catechin beverage 278 mg I2: catechin beverage 570 mg: I3: catechin beverage 845 mg C1: control beverage	Japan	12 weeks	‐	No medications that affected weight were allowed	Participants with co‐morbidities were excluded
Kovacs 2004	I1: green tea C1: placebo	The Netherlands	13 weeks	‐	Participants were excluded if taking any medications	Participants had to be in good health, no further details were provided
Kozuma 2005	I1: catechin beverage C1: placebo beverage	Japan	12 weeks	‐	Medicine, specific health foods, beverages and supplements that had the possibility of influencing lipid and glucose metabolism and other energy levels were restricted	Note: participants were excluded if had serious liver, kidney, heart disease, or diabetes
Maki  2009	I1: green tea beverage C1: control beverage	USA	12 weeks	‐	‐	‐
Nagao 2007	I1: brewed green tea beverage with added catechins C1: brewed green tea beverage with no added catechins	Japan	12 weeks	‐	Medicines or foods known to influence lipid or carbohydrate metabolism were prohibited	Participants with serious liver or renal disease were excluded
Suzuki 2009	I1: tea catechin C1: placebo	Japan	12 weeks	4‐week post‐ consumption observation period	Note: use of pharmaceutical drugs or health supplements that might affect fat metabolism discouraged Use of over‐the‐counter drugs was not allowed	Note: participants receiving medical treatment for obesity, hyperlipidaemia, diabetes or hypertension were excluded Participants with serious liver, kidney, heart, pulmonary, endocrine or metabolic disorder were excluded
Takase 2008	I1: catechin beverage C1: placebo beverage	Japan	12 weeks	‐	Medicine, food, beverages and supplements with possibility of influencing lipid and glucose metabolism and other energy levels were restricted	Participants undergoing medical treatment, with severe kidney, liver, heart disease or diabetes, were excluded. No further information available
Takashima 2004	I1: catechin beverage C1: control beverage	Japan	12 weeks	‐	Medications were not allowed	Participants with co‐morbidities were excluded
Takeshita 2008	I1: catechin beverage C1: placebo beverage	Japan	12 weeks	‐	No treatment for high blood pressure, hyperlipidaemia or diabetes	Participants with severe liver, kidney, heart disease, or diabetes were excluded
Tsuchida 2010	I1: catechin beverage C1: control beverage	Japan	12 weeks	12 weeks	Food products and medications that might affect energy absorption or lipid metabolism (e.g. dietary fibre supplements, psyllium) were restricted	‐
Wang 2010	I1: GT1 I2: GT2 I3: GT3 C1: control beverage	China	90 days	‐	No medications allowed except oral contraceptives and over‐the‐counter medications	Participants suffering from any medical or psychiatric condition were excluded
Westerterp‐ Plantenga 2005	I1: green tea‐caffeine capsule ‐ low habitual caffeine consumers I2: green tea‐caffeine capsule ‐ high habitual caffeine consumers C1: placebo ‐ low habitual caffeine consumers C2: placebo ‐ high habitual caffeine consumers	The Netherlands	3 months	‐	Medications not allowed	‐
Footnotes "‐" denotes not reported AP: adequate protein; C: control; GT: green tea; HP: high protein; I: intervention.